• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Patricia A. Ganz, Charles M. Haskell, Robert A. Figlin, N La Soto, John F. Siau
  • Medicine
  • Cancer
  • 1988 (First Published: 15 February 1988)
  • Serial assessments of Karnofsky performance status (KPS) and of the Functional Living Index--Cancer (FLIC) have been used to estimate the quality of life (QOL) of patients in a prospective,Continue Reading
  • Franz Buchegger, Charles M. Haskell, +4 authors Jean Pierre Mach
  • Medicine
  • The Journal of experimental medicine
  • 1983 (First Published: 1 August 1983)
  • Four monoclonal antibodies against carcinoembryonic antigen (CEA) have been selected from 32 hybrids that produce antibodies against this antigen, by the criteria of high affinity for CEA and lowContinue Reading
  • Hannah M. Linden, Charles M. Haskell, +8 authors Silvana Di Martino
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2007 (First Published: 9 February 2007)
  • PURPOSE We conducted a phase III randomized study of two adjuvant treatment schedules of doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration ofContinue Reading
  • W W Shih, Robert W Baumhefner, Wallace W. Tourtellotte, Charles M. Haskell, Edward L. Korn, John L. Fahey
  • Medicine
  • Clinical and experimental immunology
  • 1983 (First Published: 1 July 1983)
  • Cyclophosphamide (CY), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-fluorouracil (5-FU) were given in single course schedules to chronic progressive multiple sclerosis (MS) patientsContinue Reading
  • Raymond R. Tubbs, William Eric Barlow, +11 authors Daniel F Hayes
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Published: 20 August 2009)
  • PURPOSE Amplification and deletion of the TOP2A gene have been reported as positive predictive markers of response to anthracycline-based therapy. We determined the status of the HER2 and TOP2A genesContinue Reading